News

PCI Biotech (PCI) has initiated the phase I/II trial with the first patient treatment with its lead candidate, Amphinex. PCI’s proprietary photosensitiser Amphinex is in the study combined

Myoderm, a pharmaceutical supplier of comparator drugs for clinical research and clinical trials, has expanded its portfolio to include Distribution Management Services. Reportedly, this new capability provides their

National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health (NIH) has awarded a $30.9m, five-year contract to Nanotherapeutics. The deal is intended

OriGene Technologies has released 5,000 purified human proteins, representing comprehensive offering of human cell produced human proteins. Reportedly, OriGene’s recombinant proteins are purified from HEK293 cells transiently transfected

Aperio Technologies has received clearance from the FDA to market the IHC HER2 Breast Tissue Tunable Image Analysis application, available through its patented digital pathology platform. The application

Synexus has acquired three more clinical trial centres in Poland. Dr. Andrzej Opadczuk will continue to manage the centres and will report to Dr. Christian Tueni, vice president,

NovaDel has received a milestone payment of approximately $150,000 from Velcera relating to its License and Development Agreement with the latter. The agreement provides Velcera with a license

Warner Chilcott has proposed to acquire Procter & Gamble’s prescription-drug business. Warner Chilcott is likely to pay $3 billion for the business unit. Wall Street Journal has reported

Valeant has reported preliminary results from its phase IIa proof-of-concept clinical trial of retigabine, for the treatment of pain associated with postherpetic neuralgia (PHN). Reportedly, retigabine was generally